

Nicola Cascavilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9988068/publications.pdf>

Version: 2024-02-01

122
papers

5,077
citations

136950

32
h-index

95266

68
g-index

123
all docs

123
docs citations

123
times ranked

5998
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1759-1769.	27.0	692
2	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	27.0	664
3	Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. <i>Blood</i> , 2002, 99, 863-871.	1.4	325
4	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	10.7	254
5	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.	1.4	178
6	Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. <i>Leukemia Research</i> , 2011, 35, 363-368.	0.8	128
7	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.	1.4	109
8	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	1.6	107
9	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	5.8	103
10	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	10.7	100
11	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 974-981.	1.4	99
12	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	1.6	94
13	Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2000, 64, 275-281.	4.1	91
14	Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. <i>Leukemia and Lymphoma</i> , 2011, 52, 771-775.	1.3	86
15	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq1 1 0.784314 rgBT /Overloc 4.6 79	4.6	79
16	CD38 Expression Correlates with Adverse Biological Features and Predicts Poor Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 42, 109-114.	1.3	76
17	Clinicoprognostic implications of simultaneous increased serum levels of soluble CD23 and β_2 -microglobulin in B-cell chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 1999, 62, 117-122.	2.2	75
18	Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. <i>American Journal of Hematology</i> , 2009, 84, 636-640.	4.1	75

#	ARTICLE	IF	CITATIONS
37	Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1072-1080.	1.3	30
38	Treatment of "Poor Risk" Acute Myeloid Leukemia with Fludarabine, Cytarabine and G-CSF (Flag) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.5	29
39	Symptomatic Venous Thromboembolism and Thrombophilic Status in Adult Acute Leukemia: A Single-Center Experience of 114 Patients at Diagnosis. <i>Acta Haematologica</i> , 2007, 117, 215-220.	1.4	29
40	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	3.5	29
41	Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilms' tumor 1 expression. <i>Leukemia Research</i> , 2015, 39, 138-143.	0.8	27
42	Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.3	26
43	Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilms' tumor 1 levels. <i>Annals of Hematology</i> , 2014, 93, 1149-57.	1.8	26
44	Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies. , 1998, 58, 255-262.		24
45	Minimally Differentiated Acute Myeloid Leukemia (AML M0): Clinico-Biological Findings of 29 Cases. <i>Leukemia and Lymphoma</i> , 2000, 37, 105-113.	1.3	24
46	Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. <i>British Journal of Haematology</i> , 2003, 123, 746-747.	2.5	22
47	Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. <i>European Journal of Haematology</i> , 2009, 82, 235-239.	2.2	22
48	Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. <i>European Journal of Haematology</i> , 2010, 85, 502-507.	2.2	22
49	Clinical Relevance of Immunocytochemical Detection of Multidrug-Resistance-Associated P-Glycoprotein in Hematologic Malignancies. <i>Tumori</i> , 1990, 76, 353-359.	1.1	21
50	Morphologically Typical and Atypical B-Cell Chronic Lymphocytic Leukemias Display a Different Pattern of Surface Antigenic Density. <i>Leukemia and Lymphoma</i> , 2001, 42, 649-654.	1.3	21
51	Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis. <i>Leukemia and Lymphoma</i> , 2004, 45, 1219-1222.	1.3	21
52	Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. <i>Leukemia and Lymphoma</i> , 2011, 52, 701-704.	1.3	19
53	Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 174-179.	2.1	19
54	Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 216-225.	1.5	19

#	ARTICLE	IF	CITATIONS
55	Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. <i>Clinical Drug Investigation</i> , 2011, 31, 745-758.	2.2	18
56	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 404-408.	0.4	18
57	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1814-1822.	2.0	18
58	Serum Beta2-Microglobulin in Malignant Lymphoproliferative Disorders. <i>Tumori</i> , 1988, 74, 129-135.	1.1	17
59	Immunophenotype of Acute Lymphoblastic Leukemia Cells: The Experience of the Italian Cooperative Group (Gimema). <i>Leukemia and Lymphoma</i> , 1993, 9, 221-228.	1.3	17
60	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. <i>Leukemia Research</i> , 2006, 30, 283-285.	0.8	17
61	An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 481-489.	2.5	17
62	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	3.5	17
63	Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2021, 100, 429-436.	1.8	17
64	Inability of Activated Cord Blood T Lymphocytes to Perform Th1-like and Th2-like Responses: Implications for Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 381-385.	1.8	16
65	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. <i>British Journal of Haematology</i> , 2016, 172, 111-121.	2.5	16
66	<sc>CD</sc>117<sc>CD</sc>15 in acute myeloid leukemia: no role as <sc>LAIP</sc> in the study of minimal residual disease. <i>European Journal of Haematology</i> , 2013, 90, 171-174.	2.2	15
67	Immunophenotypic Profile of AC133-Positive Cells in Bone Marrow, Mobilized Peripheral Blood and Umbilical Cord Blood. <i>Leukemia and Lymphoma</i> , 2002, 43, 869-873.	1.3	12
68	A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>European Journal of Haematology</i> , 2020, 104, 435-442.	2.2	12
69	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. <i>Blood</i> , 2011, 118, 475-475.	1.4	12
70	Active caspase-3 detection to evaluate apoptosis induced by Verbena officinalis essential oil and citral in chronic lymphocytic leukaemia cells. <i>Revista Brasileira De Farmacognosia</i> , 2011, 21, 869-873.	1.4	12
71	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
72	Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 195-200.	1.5	11

#	ARTICLE	IF	CITATIONS
73	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	1.3	11
74	Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2008, 8, 62-68.	1.2	10
75	A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity score weighted multicenter approach. <i>American Journal of Hematology</i> , 2017, 92, E557-E559.	4.1	10
76	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	3.7	10
77	Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 35-40.	0.4	10
78	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. <i>European Journal of Haematology</i> , 2020, 104, 581-587.	2.2	10
79	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	1.3	10
80	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
81	Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2018, 97, 1817-1824.	1.8	9
82	The Significance of Minimal Residual Disease in Stem Cell Grafts and the Role of Purging: Is It Better to Purge in vivo or in vitro?. <i>Acta Haematologica</i> , 2005, 114, 206-213.	1.4	8
83	Increased serum bilirubin level without jaundice in patients with monoclonal gammopathy. <i>Leukemia and Lymphoma</i> , 2009, 50, 1392-1394.	1.3	8
84	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	2.5	8
85	Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the Rete Ematologica Pugliese E Basilicata. <i>Leukemia and Lymphoma</i> , 2019, 60, 3565-3568.	1.3	8
86	Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1449-1455.	1.8	8
87	Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. <i>Cancers</i> , 2019, 11, 1417.	3.7	7
88	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3695-3703.	7.0	7
89	Autologous stem cell transplantation in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 220-224.	0.8	7
90	Are "Early" and "Late" T-Acute Lymphoblastic Leukemias Different Diseases? A Single Center Study of 34 Patients. <i>Leukemia and Lymphoma</i> , 1996, 21, 437-442.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Usefulness of RA and RO Isoforms of Common Leukocyte Antigen (CD45) for Early Distinction Between Normal and Abnormal Promyelocytes. <i>Leukemia and Lymphoma</i> , 2002, 43, 1823-1825.	1.3	6
92	Ruxolitinib " better prognostic impact in low-intermediate 1 risk score: evaluation of the "rete ematologica pugliese"™ (REP) in primary and secondary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 138-144.	1.3	6
93	Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2008, 142, 852-853.	2.5	5
94	Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP). <i>Leukemia Research</i> , 2015, 39, 1166-1171.	0.8	5
95	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	2.2	5
96	Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 1988, 28, 213-218.	4.1	4
97	Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. <i>Annals of Hematology</i> , 2012, 91, 527-532.	1.8	4
98	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2014, 99, e159-e161.	3.5	4
99	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2687.	4.3	4
100	Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 751-755.	2.0	4
101	Everyday palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese". <i>Cancer Medicine</i> , 2020, 9, 170-178.	2.8	4
102	Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL. <i>Blood</i> , 2015, 126, 1999-1999.	1.4	4
103	Attenuated doses of rituximab for the treatment of adults with autoimmune cytopenias. <i>American Journal of Hematology</i> , 2008, 83, 686-687.	4.1	3
104	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. <i>Leukemia and Lymphoma</i> , 2019, 60, 3482-3492.	1.3	3
105	Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the Tj ETQq1 1.0.784314 rgBT /Ov	1.0.784314	3
106	Is the scoring system an effective clinico-biological tool in myeloid antigen positive adult acute lymphoblastic leukemia? Results of a long-term study. <i>The Hematology Journal</i> , 2002, 3, 251-258.	1.4	3
107	Schnitzler syndrome. <i>British Journal of Haematology</i> , 2008, 143, 152-152.	2.5	2
108	Timing of clopidogrel loading dose on peripheral blood endothelial progenitor cells, SDF-1 α and neointimal hyperplasia in carotid stenting. <i>Clinical Hemorheology and Microcirculation</i> , 2019, 72, 23-38.	1.7	2

#	ARTICLE	IF	CITATIONS
109	Feasibility of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study. <i>Blood</i> , 2015, 126, 66-66.	1.4	2
110	Corticosteroid-Induced Apoptosis in Hematological Malignancies. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2009, 8, 38-46.	1.1	1
111	Postpartum haemorrhage in a woman with essential thrombocythemia carrying calreticulin mutation. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 727-728.	1.0	1
112	Log reduction of leukemic cells and minimal residual disease by flow cytometry represent effective predictors of clinical outcome in elderly patients with acute myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 102, 26.	1.5	1
113	Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy. <i>Blood</i> , 2012, 120, 5200-5200.	1.4	1
114	Combined fine needle cytology and flow cytometry immunophenotyping for diagnosis of lymphoid disorders. <i>Leukemia and Lymphoma</i> , 2008, 49, 1212-1213.	1.3	0
115	Long-Lasting Response of Chronic Lymphocytic Leukemia and Multiple Sclerosis in a Patient Treated with Oral Fludarabine Alone. <i>Tumori</i> , 2009, 95, 406-407.	1.1	0
116	Association between proteomic profile and molecular response in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1016-1018.	1.3	0
117	Pooled-analysis of Lipegfilgrastim Effectiveness and Safety Among Patients With Blood Malignancies in the Real-world Setting. <i>Anticancer Research</i> , 2021, 41, 347-354.	1.1	0
118	Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy. <i>Blood</i> , 2012, 120, 50623-50623.	1.4	0
119	Bone Marrow (BM) Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. <i>Blood</i> , 2015, 126, 1570-1570.	1.4	0
120	Quality of Life in Elderly Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. <i>Blood</i> , 2015, 126, 2120-2120.	1.4	0
121	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients. <i>Blood</i> , 2015, 126, 2122-2122.	1.4	0
122	Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. <i>Journal of Clinical Medicine</i> , 2021, 10, 5702.	2.4	0